Cargando…

Automated Synthesis of (68)Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting

The new minigastrin analog DOTA-MGS8 targeting the cholecystokinin-2 receptor (CCK2R) used in this study displays the combination of two site-specific modifications within the C-terminal receptor binding sequence together with an additional N-terminal amino acid substitution preventing fast metaboli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hörmann, Anton Amadeus, Plhak, Elisabeth, Klingler, Maximilian, Rangger, Christine, Pfister, Joachim, Schwach, Gert, Kvaternik, Herbert, von Guggenberg, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949806/ https://www.ncbi.nlm.nih.gov/pubmed/35335396 http://dx.doi.org/10.3390/molecules27062034

Ejemplares similares

Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
por: Hörmann, Anton A., et al.
Publicado: (2021)

Automated Synthesis of [(68)Ga]Ga-FAPI-46 on a Scintomics GRP Synthesizer
por: Plhak, Elisabeth, et al.
Publicado: (2023)

Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m
por: Klingler, Maximilian, et al.
Publicado: (2019)

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting
por: Klingler, Maximilian, et al.
Publicado: (2018)

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum
por: Klingler, Maximilian, et al.
Publicado: (2019)

Correction: Klingler, M., et al. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m. Pharmaceuticals 2019, 12, 13
por: Klingler, Maximilian, et al.
Publicado: (2019)

Exploiting the Concept of Multivalency with (68)Ga- and (89)Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression
por: Summer, Dominik, et al.
Publicado: (2018)

Effect of N-Terminal Peptide Modifications on In Vitro and In Vivo Properties of (177)Lu-Labeled Peptide Analogs Targeting CCK2R
por: Hörmann, Anton Amadeus, et al.
Publicado: (2023)

Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
por: von Guggenberg, Elisabeth, et al.
Publicado: (2021)

Preclinical Assessment of a (68)Ga-DOTA-Functionalized Depsipeptide as a Radiodiagnostic Infection Imaging Agent
por: Ebenhan, Thomas, et al.
Publicado: (2017)

Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs
por: Zavvar, Taraneh Sadat, et al.
Publicado: (2023)

Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements via the Inclusion of Proline into the Peptide Sequence
por: Klingler, Maximilian, et al.
Publicado: (2020)

Preparation and preclinical evaluation of (68)Ga-DOTA-amlodipine for L-type calcium channel imaging
por: Firuzyar, Tahereh, et al.
Publicado: (2016)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Radioiodination and Purification of [(131)I]β-CIT and [(131)I]FP-CIT with an Automated Radiosynthesizer
por: Plhak, Elisabeth, et al.
Publicado: (2022)

Preparation and Biological Study of (68)Ga-DOTA-alendronate
por: Fakhari, Ashraf, et al.
Publicado: (2016)

Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177
por: Hörmann, Anton Amadeus, et al.
Publicado: (2020)

Automated preparation of clinical grade [(68)Ga]Ga-DOTA-CP04, a cholecystokinin-2 receptor agonist, using iPHASE MultiSyn synthesis platform
por: Haskali, Mohammad B., et al.
Publicado: (2019)

Initial Clinical Experience with (68)Ga-DOTA-NOC Prepared Using (68)Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based (68)Ge/(68)Ga Generator and Freeze-dried DOTA-NOC Kits
por: Chandra, Piyush, et al.
Publicado: (2017)

Diagnostic value of two-time point [(68)Ga]Ga-PSMA-11 PET/CT in the primary staging of untreated prostate cancer
por: Weitzer, Friedrich, et al.
Publicado: (2023)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Adventures in radiosynthesis of clinical grade [(68)Ga]Ga-DOTA-Siglec-9
por: Käkelä, Meeri, et al.
Publicado: (2018)

[(68)Ga]Ga-DOTA-TATE uptake due to COVID-19 vaccination
por: Weiler-Sagie, Michal, et al.
Publicado: (2021)

Physiological Biodistribution of (68)Ga-DOTA-TATE in Normal Subjects
por: Özgüven, Salih, et al.
Publicado: (2021)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Development of in-House Synthesis and Quality Control of [(99m)Tc]Tc-PSMA-I&S
por: Plhak, Elisabeth, et al.
Publicado: (2023)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Head-to-Head Comparison of (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study
por: Hou, Guozhu, et al.
Publicado: (2022)

PET-CT imaging of pulmonary inflammation using [(68)Ga]Ga-DOTA-TATE
por: Puuvuori, Emmi, et al.
Publicado: (2022)

Occupational radiation exposure assessment during the management of [(68)Ga]Ga-DOTA-TOC
por: Riveira-Martin, Mercedes, et al.
Publicado: (2022)

Standardized image quality for (68)Ga-DOTA-TATE PET/CT
por: Cox, Christina P. W., et al.
Publicado: (2020)

Assessment of regional pulmonary blood flow using (68)Ga-DOTA PET
por: Velasco, Carlos, et al.
Publicado: (2017)

Pancreatic serous cystoadenoma (CSA) showing increased tracer uptake at 68-GaDOTA-peptide Positron Emission Tomography (68Ga-DOTA-peptide PET-CT): a case report
por: Nappo, Gennaro, et al.
Publicado: (2020)

Synthesis of a DOTA-C-glyco bifunctional chelating agent and preliminary in vitro and in vivo study of [(68)Ga]Ga-DOTA-C-glyco-RGD
por: Mangin, Floriane, et al.
Publicado: (2021)

Kinetic Modelling of [(68)Ga]Ga-DOTA-Siglec-9 in Porcine Osteomyelitis and Soft Tissue Infections
por: Jødal, Lars, et al.
Publicado: (2019)

The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
por: Novruzov, Fuad, et al.
Publicado: (2021)

Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG Uptake in Esophageal Cancer
por: Liu, Huipan, et al.
Publicado: (2022)

Synthesis and Radiolabelling of DOTA-Linked Glutamine Analogues with (67,68)Ga as Markers for Increased Glutamine Metabolism in Tumour Cells
por: Pellegrini, Paul A., et al.
Publicado: (2013)

(68)Ga-DOTA-Siglec-9 – a new imaging tool to detect synovitis
por: Virtanen, Helena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o11jn1otsgr2ie1jr7aqv5q3jk